Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Christmas Dinner Warning for Ozempic Users: 'Food Was Bubbling Up' - Featured image
Health

Christmas Dinner Warning for Ozempic Users: 'Food Was Bubbling Up'

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 24, 2025·4 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Allison Rankin recounts her experience of discomfort and vomiting after overeating at a family Christmas dinner while taking Mounjaro. Doctors caution against overeating on weight loss drugs due to slowed digestion.

Share

Christmas Dinner Warning for Ozempic Users: 'Food Was Bubbling Up'

Allison Rankin was looking forward to her family's annual Christmas gathering.

In 2022, she traveled to Indiana, where her aunt transformed her living room and garage to accommodate the extended family of 60 for the holiday.

However, that particular year was different because Rankin, then 45 and residing in Boston, Massachusetts, had recently begun taking Mounjaro, a weight-loss medication.

Having been on the medication for roughly three months, she had shed 20lbs from her initial weight of 190lbs, bringing her closer to the obese range for her 5ft 7in frame.

Upon arriving at the party, she chose to keep her medication use private, as the drug was scarce at the time, and she feared accusations of depriving type 2 diabetics, for whom the drug was originally intended.

Rankin acted normally, greeting relatives and enjoying a glass of champagne before filling her plate with macaroni and cheese, pie, turkey, and gravy.

In a recent interview, she recalled that about an hour after starting her meal, she felt something was amiss.

'I just had that feeling... that feeling where you are going to throw up,' she explained. 'I felt like if I could throw up right then, I would. There was enough food bubbling at the top of my throat.'

She had eaten too much.

Physicians advise against overeating while using weight loss medications because these drugs slow down the digestive process, potentially leading to vomiting.

'When you overindulge at a buffet, you can usually just breathe through it,' Rankin, now 48, stated.

'But on a GLP-1, that won't happen. The food simply sits in your stomach. I experienced the [cold sweat] and the sensation of being about to explode.'

She recounted going pale, experiencing alternating chills and hot flashes, before excusing herself to the restroom.

Once in the bathroom, Rankin induced vomiting, expelling the undigested meal.

'It was solid food,' she remembered. 'It hadn't digested at all.'

After cleaning up, Rankin returned to the party and continued eating. She mentioned that no one noticed the incident.

This was the second instance of Rankin privately vomiting at a family gathering while on the drug. The first occurred at Thanksgiving after starting Mounjaro in late September 2022. She reported identical experiences at both events. Health tracking apps like Shotlee can help monitor eating habits and potential side effects.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Rankin shed 50lbs in six to eight months using Mounjaro and Zepbound, both containing the active ingredient tirzepatide.

Rankin had been trying to lose weight for years. She had tried the Atkins and Paleo diets, as well as reducing her calorie intake, but she said that nothing had worked.

She often worried about her health because of her weight. Many members of her family were at least 40 to 50lbs overweight, and several had heart problems.

Her father and uncle had experienced heart attacks, while her aunt and sister both required a quadruple bypass.

After starting Mounjaro, Rankin initially made mistakes, such as consuming only 600 calories daily due to a lack of hunger. She also suffered from nausea as a symptom, though she had not vomited previously.

Following these vomiting episodes, Rankin, who co-founded MyCompanionBox, a company providing food samples to weight-loss drug users, made changes. She began eating protein-rich meals and attending exercise classes.

Rankin lost 50lbs in six to eight months on Mounjaro and Zepbound (another GLP-1 agonist), averaging about 7lbs per month. After reaching her target weight of 140lbs, she gained back 10lbs because friends thought she looked gaunt.

She currently takes 10mg of Zepbound weekly and plans to continue the medication.

Rankin now feels more comfortable with her medication use and weight management.

She now selects only the foods she wants to eat and spreads them out on her plate, leaving empty space to avoid overfilling it.

However, dealing with unsolicited advice remains challenging.

'In my family, nothing is ever quite right, and they'll comment on everything you do,' she stated.

'If you're overweight and eat too much, they criticize you. If you're skinnier, they tell you to eat more because they aren't used to seeing you eat like a thin person.'

After years of practice, Rankin has achieved self-acceptance.

'I openly share my GLP-1 use and my involvement in a GLP-1-related business. It has helped me, and I'm comfortable with that,' she said.

'By discussing it, I hope to educate others who are worried or curious about the drug.'

Source Information

Originally published by Daily Mail Online.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Beyond the Scale: GLP-1 Users & the Exercise Paradox
Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read
GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight
Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Same topic: weight loss drugs

All weight loss drugs articles →
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
GLP-1 Medications

Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron

US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.

5 min read
Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks
GLP-1 Medications

Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks

Wegovy, Ozempic, and Mounjaro promise effortless weight loss with minimal risk, but new research uncovers deeper dangers like altered brain chemistry and loss of desire. On The Spectacle Podcast, Scott McKay and Melissa Mackenzie dive into the science, Melissa's personal story, and why lifestyle changes offer a safer path.

5 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Telehealth & GLP-1

Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs

Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.

5 min read

More in Health

Beyond the Headlines: Navigating Severe GLP-1 Side Effects
Health & Wellness

Beyond the Headlines: Navigating Severe GLP-1 Side Effects

Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.

7 min read
Beyond the Headlines: New GLP-1 Side Effects Uncovered on Reddit?
Health & Wellness

Beyond the Headlines: New GLP-1 Side Effects Uncovered on Reddit?

A groundbreaking study utilized AI to sift through over 400,000 Reddit posts, uncovering potential new side effects associated with popular GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. This research highlights the growing role of real-world data in understanding medication safety.

8 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read
Share this article
  1. Home
  2. Blog
  3. Christmas Dinner Warning for Ozempic Users: 'Food Was Bubbling Up'
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community